Circulating levels of visfatin/pre-B-cell colony-enhancing factor 1 in relation to genotype, GFR, body composition, and survival in patients with CKD.
about
Adipocytokines in renal transplant recipientsVisfatin: a new player in mesangial cell physiology and diabetic nephropathyInflammatory Cytokines as Uremic Toxins: "Ni Son Todos Los Que Estan, Ni Estan Todos Los Que Son".Elevated body mass index as a risk factor for chronic kidney disease: current perspectives.Visfatin-induced lipid raft redox signaling platforms and dysfunction in glomerular endothelial cells.Membrane raft-lysosome redox signalling platforms in coronary endothelial dysfunction induced by adipokine visfatinProtein-energy wasting and mortality in chronic kidney disease.Nampt/PBEF/visfatin serum levels: a new biomarker for retinal blood vessel occlusions.Sirtuins and their relevance to the kidney.Inflammatory mechanisms in the regulation of insulin resistance.Association between serum visfatin and carotid atherosclerosis in diabetic and non-diabetic patients on maintenance hemodialysisIncreased Circulating Visfatin Is Associated With Progression of Kidney Disease in Non-Diabetic Hypertensive Patients.Visfatin/Nampt: an adipokine with cardiovascular impactPre-B cell colony enhancing factor (PBEF), a cytokine with multiple physiological functions.Review article: Biomarkers of clinical outcomes in advanced chronic kidney disease.Adipokine Serum visfatin level in pregnancy induced hypertension and uncomplicated pregnancy.PBEF/NAMPT/visfatin: a promising drug target for treating rheumatoid arthritis?Proteomic biomarkers in kidney disease: issues in development and implementation.Visfatin stimulates a cellular renin-angiotensin system in cultured rat mesangial cells.Visfatin-induced expression of inflammatory mediators in human endothelial cells through the NF-kappaB pathway.Ethnic-specific correlations of visfatin with circulating markers of endothelial inflammation and function.Circulating resistin is a significant predictor of mortality independently from cardiovascular comorbidities in elderly, non-diabetic subjects with chronic kidney disease.Neuronal protective role of PBEF in a mouse model of cerebral ischemiaPlasma levels of PBEF/Nampt/visfatin are decreased in patients with liver cirrhosis.Serum levels of the adipokine visfatin are increased in pre-eclampsia.The association between plasma visfatin levels and ED.Serum Visfatin, Fetuin-A, and Pentraxin 3 Levels in Patients With Psoriasis and Their Relation to Disease Severity.Salivary visfatin concentrations in patients with chronic periodontitis.
P2860
Q26747604-83C2F8A8-A502-430B-A5FD-A490765BCBD1Q28577873-716E67E2-4C99-47A8-BF71-F4FAB03E4CBBQ33611989-ACCA51AB-0BC8-4E63-A603-93510B6FC82BQ34005600-CF07FEB6-F596-4A25-BDBE-02A9E2D362F4Q34235479-24434312-CCC8-4B0A-9E01-1F8122937AB0Q34485791-3D2694F1-9981-4A17-805F-310F95100F94Q35024794-B5174225-1905-4010-BB38-9B5EEBAF8B24Q35407970-C279728D-26A7-4FD6-9DF6-5B5612EBA8E9Q35923139-17DF64E7-59AC-4808-BD73-08090555B794Q36409227-8EFFBCC8-4723-4DF9-B53E-48EC0356B1D5Q36766658-116B09AC-531A-4F1B-9A7A-FBD8FDEBA67CQ36950161-0447F085-C664-41BD-9F9D-A9A8BEED7C67Q36970010-6298FCA3-65D0-4B96-A1D8-11E3B9D0E8BEQ37216851-A8FFA0F7-4C6F-477B-AEA3-A057444D7182Q37534821-BBC74D74-0782-41CE-814C-3D7421C1FB12Q37563133-912BC95A-9226-4477-8596-25083E171BEDQ38005192-77DA25C4-61B5-42FC-803D-BD292FE19D24Q38341211-9607C64D-A9A4-44FE-BABD-CA660CD617A8Q39593990-B65B28DA-09C9-4622-B574-4E8FB58DEA89Q39882720-8DE7DF9E-CE38-46BA-B26D-7FED05CAFF6CQ39884962-62DD627D-1F20-4E2D-B2D4-57D543C08AF7Q41050975-283CBA3E-7479-4E8E-ABE6-97BDD360125AQ41185582-DD29C671-BE6F-4070-9ACA-A84416EA7C2DQ46202318-6CAFA43A-9EA7-48E9-AD25-27DA6F7F7303Q46885225-F79D0E24-8A5D-475F-993E-BFF565B3C948Q51307688-D82DD390-CB3C-492B-BED5-BFBA0275B4ADQ53547582-D90C7372-CA46-41C0-AF4A-163C9C07A72CQ54602612-7081362D-1ABA-4F78-8085-69AC2E8E5DB5
P2860
Circulating levels of visfatin/pre-B-cell colony-enhancing factor 1 in relation to genotype, GFR, body composition, and survival in patients with CKD.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年学术文章
@wuu
2007年学术文章
@zh-cn
2007年学术文章
@zh-hans
2007年学术文章
@zh-my
2007年学术文章
@zh-sg
2007年學術文章
@yue
2007年學術文章
@zh
2007年學術文章
@zh-hant
name
Circulating levels of visfatin ...... survival in patients with CKD.
@en
Circulating levels of visfatin ...... survival in patients with CKD.
@nl
type
label
Circulating levels of visfatin ...... survival in patients with CKD.
@en
Circulating levels of visfatin ...... survival in patients with CKD.
@nl
prefLabel
Circulating levels of visfatin ...... survival in patients with CKD.
@en
Circulating levels of visfatin ...... survival in patients with CKD.
@nl
P2093
P50
P1476
Circulating levels of visfatin ...... survival in patients with CKD.
@en
P2093
Anders Alvestrand
Anna Witasp
Jonas Axelsson
Louise Nordfors
Martin Schalling
Mohamed E Suliman
Peter Bárány
P304
P356
10.1053/J.AJKD.2006.11.021
P577
2007-02-01T00:00:00Z